Journal article
Prospective comprehensive profiling of immune responses to COVID-19 vaccination in patients on zanubrutinib therapy
Thi HO Nguyen, Chhay Lim, Masa Lasica, Ashley Whitechurch, Surekha Tennakoon, Natalie R Saunders, Lilith F Allen, Louise C Rowntree, Brendon Y Chua, Lukasz Kedzierski, Hyon-Xhi Tan, Adam K Wheatley, Stephen J Kent, Theo Karapanagiotidis, Suellen Nicholson, Deborah A Williamson, Monica A Slavin, Constantine S Tam, Katherine Kedzierska, Benjamin W Teh
EJHAEM | WILEY | Published : 2023
DOI: 10.1002/jha2.639
Abstract
Zanubrutinib-treated and treatment-naïve patients with chronic lymphocytic leukaemia (CLL) or Waldenstrom's macroglobulinaemia were recruited in this prospective study to comprehensively profile humoral and cellular immune responses to COVID-19 vaccination. Overall, 45 patients (median 72 years old) were recruited; the majority were male (71%), had CLL (76%) and were on zanubrutinib (78%). Seroconversion rates were 65% and 77% following two and three doses, respectively. CD4+ and CD8+ T-cell response rates increased with third dose. In zanubrutinib-treated patients, 86% developed either a humoral or cellular response. Patients on zanubrutinib developed substantial immune responses following ..
View full abstractGrants
Awarded by Medical Research Future Fund
Funding Acknowledgements
BeiGene; Medical Research Future Fund, Grant/Award Numbers: 2005544, 2016062